SG11201806424TA - Therapeutic compounds - Google Patents
Therapeutic compoundsInfo
- Publication number
- SG11201806424TA SG11201806424TA SG11201806424TA SG11201806424TA SG11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- manchester
- compounds
- pct
- street
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1601703.0A GB201601703D0 (en) | 2016-01-29 | 2016-01-29 | Therapeutic compounds |
PCT/EP2017/051960 WO2017129829A1 (en) | 2016-01-29 | 2017-01-30 | Therapeutic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806424TA true SG11201806424TA (en) | 2018-08-30 |
Family
ID=55590433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806424TA SG11201806424TA (en) | 2016-01-29 | 2017-01-30 | Therapeutic compounds |
Country Status (17)
Country | Link |
---|---|
US (4) | US10696654B2 (ru) |
EP (1) | EP3408265B1 (ru) |
JP (1) | JP6898933B2 (ru) |
KR (1) | KR20180117627A (ru) |
CN (1) | CN108779098B (ru) |
AU (1) | AU2017213177B2 (ru) |
CA (1) | CA3012408C (ru) |
DK (1) | DK3408265T3 (ru) |
EA (1) | EA035188B1 (ru) |
ES (1) | ES2794622T3 (ru) |
GB (1) | GB201601703D0 (ru) |
HK (1) | HK1258727A1 (ru) |
IL (1) | IL260720B (ru) |
MY (1) | MY201535A (ru) |
SG (1) | SG11201806424TA (ru) |
WO (1) | WO2017129829A1 (ru) |
ZA (1) | ZA201805046B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2491038B1 (en) | 2009-10-23 | 2016-04-06 | Janssen Pharmaceutica N.V. | Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators |
GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
CA2960253A1 (en) | 2016-03-10 | 2017-09-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
CA3074059A1 (en) | 2017-09-01 | 2019-03-07 | Chronos Therapeutics Limited | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
WO2019063605A1 (en) | 2017-09-28 | 2019-04-04 | Boehringer Ingelheim International Gmbh | NOVEL N- (2,2-DIFLUOROETHYL) -N - [(PYRIMIDINYLAMINO) PROPANYL] ARYLCARBOXAMIDES |
GB201901142D0 (en) * | 2019-01-28 | 2019-03-20 | Heptares Therapeutics Ltd | OX1 Antagonists |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB240685A (en) | 1924-12-24 | 1925-10-08 | Donald Garvie | Improvements in one-way driving mechanism |
US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6066738A (en) | 1996-01-30 | 2000-05-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
GB9930557D0 (en) | 1999-12-23 | 2000-02-16 | Rolic Ag | Optically active materials |
WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JP2002326980A (ja) | 2001-04-27 | 2002-11-15 | Nippon Nohyaku Co Ltd | ジアミド誘導体及び農園芸用薬剤並びにその使用方法 |
JP2003012625A (ja) | 2001-06-28 | 2003-01-15 | Dainippon Ink & Chem Inc | アミド誘導体および農薬 |
JP2005509594A (ja) | 2001-07-13 | 2005-04-14 | バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド | Nadシンテターゼ阻害剤およびその使用 |
GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
US20040266732A1 (en) | 2002-09-20 | 2004-12-30 | Jorge Galvez | Therapeutic agents, methods, and treatments |
US7250415B2 (en) | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
JP4671123B2 (ja) | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ,インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
JP2007525482A (ja) | 2003-10-07 | 2007-09-06 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
EP1698335A4 (en) | 2003-12-26 | 2007-08-01 | Ono Pharmaceutical Co | AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR |
EP1732925A1 (en) | 2004-03-17 | 2006-12-20 | Altana Pharma AG | Novel n-(alkoxyalkyl)carbamoyl- substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde3/4 inhibitors |
JP4775259B2 (ja) | 2004-03-31 | 2011-09-21 | 味の素株式会社 | アニリン誘導体 |
US7511062B2 (en) | 2004-05-18 | 2009-03-31 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |
EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
EP2457901A1 (en) | 2005-03-14 | 2012-05-30 | High Point Pharmaceuticals, LLC | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
WO2006110626A1 (en) * | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Amidopropoxyphenyl orexin receptor antagonists |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
WO2007126934A2 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Amidoethylthioether orexin receptor antagonists |
US20080021024A1 (en) | 2006-06-29 | 2008-01-24 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
GB0623258D0 (en) | 2006-11-22 | 2007-01-03 | Remynd Nv | Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
CN101778827B (zh) | 2007-07-26 | 2012-10-10 | 先正达参股股份有限公司 | 杀微生物剂 |
CN101778846B (zh) | 2007-08-15 | 2012-11-14 | 埃科特莱茵药品有限公司 | 作为食欲素拮抗剂的1,2-二酰氨基-乙烯衍生物 |
EP2310361B1 (en) | 2008-08-01 | 2019-02-27 | Bayer Intellectual Property GmbH | Fungicidal n-(2-phenoxyethyl)carboxamide derivatives and their aza, thia and sila analogues |
UY32404A (es) | 2009-01-30 | 2010-08-31 | Novartis Ag | 4-aril-butan-1,3-diamidas |
EP2462138B1 (en) | 2009-08-05 | 2014-09-24 | Versitech Limited | Antiviral compounds and methods of making |
US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
WO2011073316A1 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | 4-aryl-butane-1,3-diamides |
US9000054B2 (en) | 2010-08-12 | 2015-04-07 | Senomyx, Inc. | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer |
JP5570921B2 (ja) | 2010-09-08 | 2014-08-13 | アグロカネショウ株式会社 | N−フェニルチオアルキルピラゾール−3−カルボキサミド誘導体および該誘導体を有効成分とする殺ダニ剤 |
EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
EP2532661A1 (en) | 2011-06-10 | 2012-12-12 | Syngenta Participations AG | Novel insecticides |
US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
US8946430B2 (en) | 2011-09-30 | 2015-02-03 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
US9422276B2 (en) | 2011-11-25 | 2016-08-23 | Bayer Intellectual Property Gmbh | Use of aryl and hetaryl carboxamides as endoparasiticides |
JP5830821B2 (ja) | 2012-04-11 | 2015-12-09 | アグロカネショウ株式会社 | N−チオアルキルピラゾール−3−カルボキサミド誘導体およびこれを有効成分とする殺ダニ剤 |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
BR112014031109A2 (pt) * | 2012-06-15 | 2017-06-27 | Taisho Pharmaceutical Co Ltd | derivado de anel heteroaromático de alquila de cadeia ramificada |
JP6218734B2 (ja) | 2012-08-30 | 2017-10-25 | 国立大学法人 東京大学 | 内部寄生虫防除剤 |
AU2013310075A1 (en) | 2012-08-30 | 2015-04-02 | Nihon Nohyaku Co., Ltd. | Endoparasite control agent and use thereof |
LT2897939T (lt) | 2012-09-21 | 2017-05-10 | Sanofi | Benzimidazolo karboksirūgšties amido dariniai metabolinių arba širdies ir kraujagyslių ligų gydymui |
EP2730570A1 (de) | 2012-11-13 | 2014-05-14 | Bayer CropScience AG | Pyridyloxyalkylcarboxamide und deren Verwendung als Endoparasitizide und Nematizide |
TW201444821A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
TW201444849A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
TW201613891A (en) * | 2014-02-12 | 2016-04-16 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
BR112016028119A2 (pt) | 2014-06-06 | 2017-08-22 | Res Triangle Inst | Agonistas receptores de apelina (apj) e usos dos mesmos |
GB201415569D0 (en) * | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
WO2016100161A1 (en) | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Ethyldiamine orexin receptor antagonists |
GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
-
2016
- 2016-01-29 GB GBGB1601703.0A patent/GB201601703D0/en not_active Ceased
-
2017
- 2017-01-30 CN CN201780012049.0A patent/CN108779098B/zh active Active
- 2017-01-30 EA EA201891710A patent/EA035188B1/ru not_active IP Right Cessation
- 2017-01-30 CA CA3012408A patent/CA3012408C/en active Active
- 2017-01-30 AU AU2017213177A patent/AU2017213177B2/en active Active
- 2017-01-30 KR KR1020187024851A patent/KR20180117627A/ko not_active Application Discontinuation
- 2017-01-30 SG SG11201806424TA patent/SG11201806424TA/en unknown
- 2017-01-30 WO PCT/EP2017/051960 patent/WO2017129829A1/en active Application Filing
- 2017-01-30 ES ES17703085T patent/ES2794622T3/es active Active
- 2017-01-30 EP EP17703085.5A patent/EP3408265B1/en active Active
- 2017-01-30 DK DK17703085.5T patent/DK3408265T3/da active
- 2017-01-30 JP JP2018539318A patent/JP6898933B2/ja active Active
- 2017-01-30 MY MYPI2018702606A patent/MY201535A/en unknown
- 2017-01-30 US US16/073,429 patent/US10696654B2/en active Active
-
2018
- 2018-07-22 IL IL260720A patent/IL260720B/en unknown
- 2018-07-26 ZA ZA2018/05046A patent/ZA201805046B/en unknown
-
2019
- 2019-01-22 HK HK19101128.2A patent/HK1258727A1/zh unknown
-
2020
- 2020-04-28 US US16/860,572 patent/US11130746B2/en active Active
-
2021
- 2021-08-27 US US17/459,598 patent/US11753398B2/en active Active
-
2023
- 2023-07-25 US US18/225,966 patent/US20240076282A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20180117627A (ko) | 2018-10-29 |
US20240076282A1 (en) | 2024-03-07 |
MY201535A (en) | 2024-02-28 |
CA3012408C (en) | 2023-12-12 |
IL260720A (en) | 2018-10-31 |
CN108779098A (zh) | 2018-11-09 |
JP2019503390A (ja) | 2019-02-07 |
GB201601703D0 (en) | 2016-03-16 |
AU2017213177A1 (en) | 2018-08-09 |
DK3408265T3 (da) | 2020-06-02 |
EA201891710A1 (ru) | 2019-01-31 |
HK1258727A1 (zh) | 2019-11-15 |
EP3408265B1 (en) | 2020-05-13 |
EA035188B1 (ru) | 2020-05-12 |
ES2794622T3 (es) | 2020-11-18 |
ZA201805046B (en) | 2022-03-30 |
AU2017213177B2 (en) | 2020-10-08 |
US10696654B2 (en) | 2020-06-30 |
US11130746B2 (en) | 2021-09-28 |
US20200255404A1 (en) | 2020-08-13 |
CA3012408A1 (en) | 2017-08-03 |
US20210395227A1 (en) | 2021-12-23 |
IL260720B (en) | 2021-09-30 |
WO2017129829A1 (en) | 2017-08-03 |
JP6898933B2 (ja) | 2021-07-07 |
CN108779098B (zh) | 2021-04-09 |
US11753398B2 (en) | 2023-09-12 |
EP3408265A1 (en) | 2018-12-05 |
US20190040041A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806424TA (en) | Therapeutic compounds | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201900904PA (en) | Methods for cross coupling | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction |